0000904454-13-001086.txt : 20131003
0000904454-13-001086.hdr.sgml : 20131003
20131003182206
ACCESSION NUMBER: 0000904454-13-001086
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131001
FILED AS OF DATE: 20131003
DATE AS OF CHANGE: 20131003
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ATOSSA GENETICS INC
CENTRAL INDEX KEY: 0001488039
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 264753208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4105 E MADISON STREET
STREET 2: SUITE 320
CITY: SEATTLE
STATE: WA
ZIP: 98112
BUSINESS PHONE: 206 325 6086
MAIL ADDRESS:
STREET 1: 4105 E MADISON STREET
STREET 2: SUITE 320
CITY: SEATTLE
STATE: WA
ZIP: 98112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chen Shu-Chih
CENTRAL INDEX KEY: 0001552127
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35610
FILM NUMBER: 131134993
MAIL ADDRESS:
STREET 1: C/O ATOSSA GENETICS, INC
STREET 2: 4105 E MADISON STREET, SUITE 320
CITY: SEATTLE
STATE: WA
ZIP: 98112
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-10-01
0001488039
ATOSSA GENETICS INC
ATOS
0001552127
Chen Shu-Chih
4105 E. MADISON STREET, SUITE 320
SEATTLE
WA
98112
1
1
1
0
Chief Scientific Officer
Common Stock
2013-10-01
4
S
0
7265
5.658
D
4268315
I
By Ensisheim Partners, LLC
The sales reported on this Form 4 were effected pursuant to a trading plan previously adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The trading plan was previously reviewed and approved by the Company's board of directors in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.57 to $5.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Ensisheim Partners, LLC is wholly owned by the Reporting Person and Dr. Steven Quay, the Chief Executive Officer of the Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of all such securities for purposes of Section 16 or any other purpose.
/s/ Shu-Chih Chen
2013-10-03